Category

Litigation Update: Zantac Videoconference Hearings Begin

Posted on by Edward Lott

There have been a number of groups affected by the MDL pending regarding Zantac, the popular heartburn medication. It is alleged that the defendant knew that Zantac was hazardous to consumers for years, but it became publicly known in September of 2019 that there were trace amounts of NDMA in the drug when the FDA … Continue reading “Litigation Update: Zantac Videoconference Hearings Begin”

Litigation Update: Elmiron MDL Sent to New Jersey

Posted on by Edward Lott

On Tuesday, December 15th the JPML sent all Elmiron cases to be tried in New Jersey by U.S. Judge Brian R. Martinotti. The judge had been handling Elmiron lawsuits and had already set up processes resembling those typically followed in MDLs. Because those efforts were already far along and with a majority of the plaintiffs … Continue reading “Litigation Update: Elmiron MDL Sent to New Jersey”

COVID-19’s Impact on The Mass Tort Landscape: What to Consider

Posted on by Edward Lott

When the courts closed in March 2020 due to COVID-19, few would have foreseen the impact on so many aspects of the mass tort landscape.  Judges, attorneys, defendants, and plaintiffs alike are all feeling the ripple effects of a system that was paralyzed for nearly half a year and only slowly, and under conditions that … Continue reading “COVID-19’s Impact on The Mass Tort Landscape: What to Consider”

Litigation Update: JPML to Decide on Elmiron’s Litigation Venue

Posted on by Edward Lott

At the last JPML hearing held on Thursday, December 4th, the panel heard from counsel for Johnson & Johnson and lawyers for plaintiffs. Both sides presented arguments for creating an MDL for all Elmiron cases in New Jersey federal court.  Those proposing NJ as the appropriate venue, stated that U.S. District Judge Brian Martinotti in … Continue reading “Litigation Update: JPML to Decide on Elmiron’s Litigation Venue”

Bayer’s bid to settle U.S. Roundup cancer claims making progress

Posted on by Carey Gillam

Monsanto owner Bayer AG is making progress toward a sweeping settlement of thousands of U.S. lawsuits brought by people alleging they or their loved ones developed cancer after exposure to Monsanto’s Roundup herbicides. Recent correspondence from plaintiffs’ lawyers to their clients underscored that progress, confirming a large percentage of plaintiffs are opting to participate in … Continue reading “Bayer’s bid to settle U.S. Roundup cancer claims making progress”

ForLawFirmsOnly Marketing, Inc. © 1994-2021 All Rights Reserved